JLJi Joo Lee

Ji Joo Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ji Joo Lee has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Young-Joon Park

    Division of Tuberculosis Policy, Korea Disease Control and Prevention Agency, Cheongju, Korea

    7 shared publications
  • Sang-Eun Lee

    Division of Vectors and Parasitic Diseases, Korea Disease Control and Prevention Agency (KDCA), Cheongju 28159, Republic of Korea

    6 shared publications
  • Hanul Park

    Department of Preventive Medicine, Korea University College of Medicine, Seoul, South Korea

    4 shared publications
  • Hye Young Lee

    Division of Infectious Disease Response, Chungcheong Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, Daejeon, Republic of Korea

    4 shared publications
  • Jihyun Choi

    Epidemiological Investigation Team, Central Disaster Safety and Countermeasure Headquarters, Korea Disease Control and Prevention Agency, Cheongju, Korea

    4 shared publications
  • Mi Yu

    Division of Epidemiological Investigation Analysis, Bureau of Public Health Emergency Preparedness, Korea Disease Control and Prevention Agency, Cheongju, Korea

    4 shared publications

Latest Publications

  • Open Access

    Event-based surveillance in the Republic of Korea: assessment of the effectiveness of Epidemic Intelligence from Open Sources

    by Seontae Kim, Jia Lee, Jiyoung Oh, Ji Joo Lee, Geehyuk Kim, Jaehwa Chung, Yunhee Lee, Yongmoon Kim, Sangwoo Tak

    In 2023, the Republic of Korea’s Korea Disease Control and Prevention Agency (KDCA) enhanced its event-based surveillance practices by using the World Health Organization’s (WHO) Epidemic Intelligence from Open Sources (EIOS) to actively screen and share information about potential public health threats to the country. This report describes the preliminary assessment of the results of implementing these enhanced event-based surveillance activities from June to October 2023. During this period, 425 (0.4%) events were detected globally by the KDCA from 99 945 media articles, with the highest frequency reported in Asia (185, 43.5%) and North America (81, 19.1%). The most frequently reported diseases or conditions were dengue fever (111, 26.1%) and mpox (32, 7.5%). Eight events were detected early by the KDCA using EIOS before being officially listed on WHO’s Event Information Site (EIS) or in Disease Outbreak News (DON), with an average interval of 20 days (range: 5–41) between the detection date and posting on EIS or DON. Thus, EIOS is efficient in aiding early detection of potential public health threats at the national level. This finding highlights the importance of sustaining international cooperation and support to enhance surveillance capabilities in resource-limited settings and expanding the scope of EIOS, including by incorporating additional sources and sources in additional languages, reducing noise. However, as the current report is based on a descriptive analysis, in the future a systematic evaluation of event-based surveillance using EIOS to identify relevant attributes will need to be conducted.


  • Open Access

    Preventing COVID-19 in Correctional Facilities: The Impact of Rapid Antigen Tests on Early Detection and Infection Control

    by Hye Young Lee, Young-Joon Park, Sang-Eun Lee, Ji Joo Lee, Jihyun Choi, Mi Yu, Hanul Park, Hee Seok Park, Jun Yeop Kim, Jun Young Moon

    Lee HY, et al. Infect Chemother. 2025 May;57:e36. https://doi.org/10.3947/ic.2024.0080


  • Open Access

    Evaluation of COVID-19 vaccine effectiveness in different high-risk facility types during a period of Delta variant dominance in the Republic of Korea: a cross-sectional study

    by Min Jei Lee, Myung-Jae Hwang, Dong Seob Kim, Seon Kyeong Park, Jihyun Choi, Ji Joo Lee, Jong Mu Kim, Young-Man Kim, Young-Joon Park, Jin Gwack, et al.

    Objectives: We evaluated the effectiveness of coronavirus disease 2019 vaccination in high-risk facilities in the Republic of Korea during the period when the highly transmissible Delta variant was prevalent. Additionally, we aimed to explore any disparities in vaccine effectiveness (VE) across various types of institutions, specifically distinguishing between non-medical and medical establishments. Methods: We examined 8 outbreak clusters covering 243 cases and 895 contacts from 8 high-risk facilities divided into 2 groups: group A (4 non-medical institutions) and group B (4 medical institutions). These clusters were observed from July 27, 2021 to October 16, 2021 for the attack rate (AR) and VE with respect to disease severity. A generalized linear model with a binomial distribution was used to determine the odds ratio (OR) for disease severity and death. Results: AR was notably lower in group B (medical institutions). Furthermore, VE analysis revealed that group A exhibited higher effectivity for disease severity and death than group B. The OR for disease severity was 0.24 (95% confidence interval [CI], 0.03–2.16) for group A and 0.27 (95% CI, 0.12–0.64) for group B, with the OR for death at 0.12 (95% CI, 0.01–1.32) in group A and 0.34 (95% CI, 0.14–0.87) in group B. Conclusion: Although VE may vary across institutions, our findings underscore the importance of implementing vaccinations in high-risk facilities. Customized vaccination programs, tailored response plans, and competent management personnel are essential for effectively addressing and mitigating public health challenges.

  • Open Access

    Epidemiological Characteristics of a COVID-19 Outbreak in a Psychiatric Hospital in Chung-buk

    by Se-Hyuk Jang, Young-Joon Park, Ji-Joo Lee, Woo-Jin Jung

    This study investigated the causes and risks for infection spread in three psychiatric hospitals in Chung-buk, South Korea, to strategize measures to block transmission and prevent a large-scale epidemic. From December 2020 to January 2021, 358 inpatients of Psychiatric Hospitals A, B, and C were enrolled to identify the epidemiological characteristics of confirmed patients. Epidemic curves and propagation relationships were constructed and a genotype analysis was conducted. The index case inpatient from Hospital A transmitted the infection to patients in Hospitals B and C; the infection was confirmed in 47, 193, and 118 patients in Hospitals A, B, and C, respectively. The patient characteristics hampered communication and the close identification of symptom onset. The incidence rate was 10 (2.9%) among employees and 348 (35.8%) among inpatients. The relative risk was 12.1 (95% CI: 6.6–22.5) times higher among inpatients than employees. Next-generation sequencing confirmed the probable infection source as a genotype identical to that of two different outbreaks, although the infection spread was undetermined. Direct risk factors emerged from patient characteristics, wherein cohort isolation was meaningless due to uncontrolled communication. Indirect risk factors included hospital-specific problems due to external factors (non-patient system deficiencies or employee negligence). Prior inspections, a confirmation of non-infection, and institutional emergent measures are needed.


  • Open Access

    Analysis of pregnant women with critically severe COVID-19 in Republic of Korea from February 2020 and December 2021

    by Ji Joo Lee, Sang-Eun Lee, Yeonjung Kim, Young-Joon Park

    Objectives: This study aimed to describe the characteristics and risk factors for severe disease in pregnant women infected with coronavirus disease 2019 (COVID-19) from the early days of the COVID-19 epidemic in Korea to the predominant period of the Delta variant.Methods: A retrospective cohort study was conducted among pregnant women diagnosed with COVID-19 between February 2020 and December 2021. Logistic regression analysis was performed to compare severe and mild cases after adjusting for pregnant women’s age, nationality, infection route, outbreak area, infection period, symptoms, underlying disease, smoking status, trimester, and COVID-19 vaccination status.Results: In total, 2,233 pregnant women were diagnosed with COVID-19 by December 2021. Among these, 96.7% had mild symptoms, 3.3% had severe symptoms, and 0.04% died. The risk factors for severe disease in pregnant women with confirmed COVID-19 were being in the age group of 35 to 45 years, having hyperlipidemia, being in the second or third trimester of pregnancy at the time of COVID-19 diagnosis, being infected during the Delta-predominant period, and having a fever (≥38 °C) at diagnosis. Furthermore, 47.1% of patients in the mild group and 84.9% of patients in the severe group had 3 or more risk factors.Conclusion: Pregnant women with COVID-19 mainly experienced mild symptoms, but those with risk factors were at a higher risk of developing severe symptoms. Therefore, treatment and follow-up management should be thoroughly implemented.

  • Open Access

    Accuracy of Rapid Antigen Screening Tests for SARS-CoV-2 Infection at Correctional Facilities in Korea: March - May 2022

    by Hye Young Lee, Young-Joon Park, Mi Yu, Hanul Park, Ji Joo Lee, Jihyun Choi, Hee Seok Park, Jun Yeop Kim, Jun Young Moon, Sang-Eun Lee

    Lee HY, et al. Infect Chemother. 2023 Sep;55:e41. https://doi.org/10.3947/ic.2023.0059


  • Open Access

    The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2

    by Hanul Park, Young Joon Park, Hye Young Lee, Mi Yu, Yeong-Jun Song, Sang Eun Lee, Ji-Joo Lee, Eun-Sol Lee, Yeonjung Kim

    Objectives: On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19).Methods: From February 6, 2022 to April 2, 2022, the incidence of COVID-19 and the effects of treatment with Paxlovid were analyzed in 2,241 patients and workers at 5 long-term care facilities during the outbreak of the Omicron variant of severe acute respiratory syndrome coronavirus 2 in South Korea.Results: The rate of severe illness or death in the group given Paxlovid was 51% lower than that of the non-Paxlovid group (adjusted risk ratio [aRR], 0.49; 95% confidence interval [CI], 0.24−0.98). Compared to unvaccinated patients, patients who had completed 3 doses of the vaccine had a 71% reduced rate of severe illness or death (aRR, 0.29; 95% CI, 0.13−0.64) and a 65% reduced death rate (aRR, 0.35; 95% CI, 0.15−0.79).Conclusion: Patients given Paxlovid showed a lower rate of severe illness or death and a lower fatality rate than those who did not receive Paxlovid. Patients who received 3 doses of the vaccine had a lower rate of severe illness or death and a lower fatality rate than the unvaccinated group.


  • Open Access

    Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021

    by Ji Joo Lee, Young June Choe, Hyeongseop Jeong, Moonsu Kim, Seonggon Kim, Hanna Yoo, Kunhee Park, Chanhee Kim, Sojin Choi, JiWoo Sim, et al.

    Lee JJ, et al. J Korean Med Sci. 2021 Dec;36(50):e346. https://doi.org/10.3346/jkms.2021.36.e346